This week’s most significant story came in the form of a change at the top for MindMed. On Wednesday, the company announced that JR Rahn is stepping down from his position as CEO, to be replaced by chief development officer Robert Barrow; for now, at least. Elsewhere, atai Life Sciences inches closer to IPO, with a target valuation of $2.3bn announced today. Two weeks ago, we reported on insider…


Previous articleFilament Announces First GMP Batch of Pharmaceutical Grade Natural Psilocybin
Next articlePsychedelic Research Bulletin: May 2021